The University of Liverpool’s AI diagnostic technology spin-out, AI-Sight, has successfully concluded its seven-figure equity funding round from experienced healthcare industry figures and investors.
The funders, committed to developing innovation and business in the North West of England, include Sir Michael Bibby (Chairman of the Bibby Line Group and Hon PhD, University of Liverpool), Phil Kirby (former Managing Director of InHealth Intelligence), Pitalia Capital (the family office of Anil Pitalia, Founder of SpaMedica) and Deepbridge Capital.
The round closure follows the Class 1 medical device certification of AI-Sight’s first commercial product, an AI software device designed to support training and diagnostic decision-making by human graders of diabetic retinopathy in retinal scans.
AI-Sight has also signed a research collaboration agreement with the UK’s largest specialist provider of diagnostic and healthcare solutions, the InHealth Group. This collaboration brings together industry leading healthcare solutions and the deep research and clinical experience of the AI-Sight team to accelerate the commercial study programme.
This funding round will support MHRA approval and Class 2 certification for AI-Sight’s full diagnostic platform and its launch in the UK and internationally. The platform is designed to improve patient outcomes, with additional benefits that promote efficiency in public health systems and ensure human resources are allocated to the areas of greatest need.
To find out more, CLICK HERE
